Long-term studies on the stability and oral bioavailability of cyclosporine A nanoparticle colloid

International Journal of Pharmaceutics

Volumn 322, Issue 1-2, 2006, Pages 146-153

  Wang, Xue qing ^a   Huang, Jia ^a   Dai, Jun dong ^a   Zhang, Tao ^b   Lü, Wan liang ^a   Zhang, Hua ^a   Zhang, Xuan ^a   Wang, Jian cheng ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b North China Pharmaceutical Corporation   (China)

Author keywords

Bioavailability; Cyclosporine A; Nanoparticles; Pharmacokinetics; Stability

Indexed keywords

CYCLOSPORIN A; EUDRAGIT; NANOPARTICLE; SOLVENT; UNCLASSIFIED DRUG; VANZAN; XANTHAN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COLLOID; CONCENTRATION (PARAMETERS); DIFFUSION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; EMULSION; MALE; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; RAT; STORAGE TEMPERATURE; SURFACE PROPERTY; TECHNIQUE; TRANSMISSION ELECTRON MICROSCOPY; VISCOSITY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; COLLOIDS; CYCLOSPORINE; DRUG STABILITY; DRUG STORAGE; HYDROGEN-ION CONCENTRATION; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; POLYMETHACRYLIC ACIDS; POLYSACCHARIDES, BACTERIAL; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES; TEMPERATURE; VISCOSITY;

EID: 33748288343     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.05.021     Document Type: Article

References (22)

1. Bonduelle S., Pimienta C., Benoit J.P., and Lenaerts V. Body distribution in mice of intravenously injected radiolabelled cyclosporin associated with polyisohexylcyanoacrylate nanocapsules or nanospheres. Eur. J. Pharm. Biopharm. 41 (1995) 27-30
2. Cavanak T., and Sucker H. Formulation of dosage forms. Prog. Allergy 38 (1986) 65-72
3. Chacón M., Molpeceres J., Berges L., Guzmán M., and Aberturas M.R. Stability and freeze-drying of cyclosporine loaded poly(d,l lactide-glycolide) carriers. Eur. J. Pharm. Sci. 8 (1999) 99-107
4. Dai J.D., Nagai T., Wang X.Q., Zhang T., Meng M., and Zhang Q. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int. J. Pharm. 280 (2004) 229-240
5. Dai J.D., Zhang T., Wang X.Q., Meng M., and Zhang Q. Lyophilization effect on the particle size stability of cyclosporine A pH sensitive nanoparticles. Chinese J. Pharm. 36 (2005) 548-550
6. Desai M.P., Labhasetwar V., Amidon G.L., and Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 13 (1996) 1838-1845
7. El-Shabouri M.H. Positively charged nanoparticles for improving the oral bioavailability of cyclosporine-A. Int. J. Pharm. 249 (2002) 11-108
8. Lee W.K., Park J.Y., Yang E.H., Suh H., Kim S.H., Chung D.S., Choi K., and Yang C.W. Investigation of factors influencing the release rates of cyclosporine A-loaded micro- and nanoparticles prepared by high-pressure homogenizer. J. Control. Release 84 (2002) 115-123
9. Lindholm A., Henricsson S., Lind M., and Dahlqvist R. Intra-individual variability in the relative availability of cyclosporin after oral dosing. Eur. J. Clin. Pharmacol. 34 (1988) 461-464
10. Luke D.R., Kasiske B.L., Matzke G.R., Awni W.M., and Keane W.F. Effect of cyclosporin on the isolated perfused rat kidney. Transplantation 43 (1987) 795-799
11. Matzke G.R., and Luke D.R. Dialysis and renal transplant therapy. In: Herfindal E.T., Gourley D.R., and Hart L.L. (Eds). Clinical Pharmacy and Therapeutics (1988), Williams & Wilkins, Baltimore 229-242
12. Molpeceres J., Guzmán M., Aberturas M.R., Chacón M., and Berges L. Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement. J. Pharm. Sci. 85 (1996) 206-213
13. Richardson C., and Emery P. Clinical use of cyclosporin in rheumatoid arthiritis. Drugs 50 (1995) 26-36
14. Ruxandra G., Patricia Q., Alejandro S., Pilar C., Edith D., and Maria J.A. Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur. J. Pharm. Biopharm. 51 (2001) 111-118
15. Saez A., Guzmán M., Molpeceres J., and Aberturas M.R. Freeze-drying of polycaprolactone and poly(d,l-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs. Eur. J. Pharm. Biopharm. 50 (2000) 379-387
16. Sajjadi H., Soheilian M., Ahmadieh H., Hussanein K., Parvin M., Azarmina M., Ehyaee V., and Amiransari B. Low dose cyclosporin-A therapy in Behcet's disease. J. Ocul. Pharmacol. 10 (1994) 553-560
17. Sánchez A., and Alonso M.J. Poly(d,l-lactide-co-glycolide) micro and nanospheres as a way to prolong blood plasma levels of subcutaneously injected cyclosporin A. Eur. J. Pharm. Biopharm. 41 (1995) 31-37
18. Urata T., Arimori K., and Nakano N. Modification of the release rate of cyclosporin A from poly(l-lactic acid) microspheres by fatty acid ester and in vivo evaluation of the microspheres. J. Control. Release 58 (1999) 133-141
19. Venkataram S., Awni W.M., Jordan K., and Rahman Y.E. Pharmacokinetics of two alternative dosage forms of cyclosporin: liposomes and intralipid. J. Pharm. Sci. 79 (1990) 216-219
20. Wang X.Q., Dai J.D., Chen Z., Zhang T., Xia G.M., Nagai T., and Zhang Q. Bioavailability and pharmaceutics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration. J. Control. Release 97 (2004) 421-429
21. Yanagawa A., Iwayama T., Saotome T., Shoji Y., Takano K., Oka H., Nakagawa T., and Mizushima Y. Selective transfer of cyclosporin to thoracic lymphatic systems by the application of lipid microspheres. J. Microencapsul. 6 (1989) 161-164
22. Zhang Q., Yie G., Li Y., Yang Q., and Nagai T. Studies on the cyclosporine A loaded stearic acid nanoparticcles. Int. J. Pharm. 200 (2000) 153-159